The present disclosure relates to compounds of Formula (I), (II), or (II′): (I), (II), (II′), and pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds and therapeutic and diagnostic uses of the compounds and pharmaceutical compositions.

##STR00001##

The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.

Provided herein are compounds of formula (I) and compositions containing the compounds. The compounds and compositions are useful in the methods of treating, amelioration or prophylaxix of diseases associated with Nrf2/NF-.sub.κB pathways. The diseases associated include, but are not limited to a fibrotic disease such as lung fibrosis, liver fibrosis, kidney fibrosis, and scleroderma, or a neurodegenerative disease, such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, and Alzheimer's disease, and sickle cell disease.

##STR00001##

This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermatological disorders and conditions. This invention is also directed to pharmaceutical compositions comprising analogs of TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration.

This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermatological disorders and conditions. This invention is also directed to pharmaceutical compositions comprising analogs of TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration.

The present invention is directed to a monomer for chain growth polymerization, in particular anionic polymerization, said monomer having the general formula (EFL)

##STR00001##

wherein: R.sup.a is a C.sub.1-C.sub.30 alkyl, C.sub.3-C.sub.30 cycloalkyl, C.sub.6-C.sub.18 aryl or C.sub.2-C.sub.12 alkenyl group. The present invention is further directed to a process for the anionic polymerization of at least one compound (EFL) as defined above, wherein said anionic polymerization is conducted in the presence of an initiator selected from the group consisting of: alkali metal organyls; alkali metal alkoxides; alkali metal thiolate; alkali metal amides; and compounds of an element of group 3a of the Periodic Table of the Elements. The process of anionic polymerization yields a homo- or co-polymer (p-EFL) having pendant lactone functional groups in its repeating units.

The present invention is directed to a monomer for chain growth polymerization, in particular anionic polymerization, said monomer having the general formula (EFL)

##STR00001##

wherein: R.sup.a is a C.sub.1-C.sub.30 alkyl, C.sub.3-C.sub.30 cycloalkyl, C.sub.6-C.sub.18 aryl or C.sub.2-C.sub.12 alkenyl group. The present invention is further directed to a process for the anionic polymerization of at least one compound (EFL) as defined above, wherein said anionic polymerization is conducted in the presence of an initiator selected from the group consisting of: alkali metal organyls; alkali metal alkoxides; alkali metal thiolate; alkali metal amides; and compounds of an element of group 3a of the Periodic Table of the Elements. The process of anionic polymerization yields a homo- or co-polymer (p-EFL) having pendant lactone functional groups in its repeating units.

A method of treatment or prevention of fibrosis of human tissue or organ. The method includes administering a patient in need thereof a compound of formula (I).

Provided are compounds of Formula (II) that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided. ##STR00001##

Provided are compounds of Formula (II) that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided. ##STR00001##